Despite losing a $10 billion bid for Metsera to Pfizer, Novo Nordisk's CEO Mike Doustdar remains determined to pursue new opportunities in the obesity and diabetes sectors. The company aims to reclaim its position in the booming weight-loss market.
In a bold move, Pfizer has filed a lawsuit against Novo Nordisk and Metsera, claiming their merger violates antitrust laws and threatens competition in the obesity drug market.
New research reveals that COVID-19 vaccines like Pfizer and Moderna could enhance the effectiveness of cancer treatments for patients with advanced lung or skin cancer, potentially doubling survival rates. Discover how mRNA technology is reshaping cancer therapy!
In a significant announcement, President Trump is set to reveal a new drug pricing deal with AstraZeneca, following a similar agreement with Pfizer. This move aims to lower U.S. drug prices and pressure major drugmakers to bring manufacturing back to America. Will it lead to real savings for taxpayers?
In a bold move to reduce U.S. prescription drug prices, AstraZeneca and Pfizer have struck deals with the White House, promising significant discounts for patients. This comes amid rising pressure from President Trump on drugmakers to lower costs or face hefty tariffs. Will these changes truly benefit American patients?
Pfizer's unexpected deal with the Trump administration on drug pricing sends shockwaves through the pharmaceutical industry, pressuring competitors to follow suit amidst potential regulatory threats. What’s next for drug prices?
President Trump reveals plans for a new website, TrumpRx, aimed at providing discounted prescription medications directly to Americans, particularly benefiting low-income families. This initiative follows Pfizer's agreement to lower drug prices, promising a transformative approach to healthcare access.
President Trump is set to unveil a new strategy to lower drug costs, including the launch of a 'TrumpRx' website for discounted medications and a deal with Pfizer. This move aims to tackle high prescription prices that burden American patients.
President Trump announces major changes to prescription drug pricing, with Pfizer leading the way. Discover how U.S. patients will benefit from this new initiative and what it means for the future of healthcare.
Pfizer is making headlines with its $7.3 billion acquisition of Metsera, a weight loss drugmaker, as it aims to capture a share of the booming obesity drug market. This deal highlights the growing demand for innovative obesity treatments and Pfizer's strategic pivot following setbacks in its own drug pipeline.